Dosage protocol · Metabolic & Weight Loss
Semaglutide 5 mg
Weekly dose range: 250–2400 mcg (0.25–2.4 mg) once weekly (gradual escalation protocol).
- Reconstitute: Add 2.0 mL bacteriostatic water → ~2.5 mg/mL concentration.
- Weekly dose range: 250–2400 mcg (0.25–2.4 mg) once weekly (gradual escalation protocol).
- Easy measuring: At 2.5 mg/mL, 1 unit = 0.01 mL ≈ 25 mcg on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 28 days.
Reconstitution
Semaglutide dosage chart
| Week | Week | Draw |
|---|---|---|
| Weeks 1–4 | 250 mcg (0.25 mg) | 10 units0.10 mL |
| Weeks 5–8 | 500 mcg (0.5 mg) | 20 units0.20 mL |
| Weeks 9–12 | 1000 mcg (1.0 mg) | 40 units0.40 mL |
| Weeks 13–16 | 1700 mcg (1.7 mg) | 68 units0.68 mL |
| Weeks 17+ (Maintenance) | 2400 mcg (2.4 mg) | 96 units0.96 mL |
How much to draw
The Draw column shows exactly where to stop on a U-100 insulin syringe. Different vial size or dose? The calculator below recomputes it live.
Supplies needed
Supplies needed
Peptide vial
The lyophilized compound
Bacteriostatic water
For reconstitution
U-100 insulin syringes
One per injection
Alcohol swabs
Stopper + site each time
How it works
Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1), an incretin hormone the body releases after eating to help regulate blood sugar and appetite.[1] Structural modifications — including a fatty-acid side chain that promotes albumin binding and resistance to enzymatic breakdown — extend its half-life to roughly a week, supporting once-weekly dosing in injectable form.[2]
Semaglutide is the active ingredient in three FDA-approved prescription products: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management, each with its own approved indication, dose, and label.[3] This approved pharmaceutical status is distinct from the unapproved, compounded, and "research peptide" semaglutide products discussed below.
Benefits & side effects
Semaglutide has one of the most extensive human evidence bases of any peptide drug, spanning the STEP program for weight management, the SUSTAIN and PIONEER programs for type 2 diabetes, and dedicated cardiovascular-outcomes trials.[5] In the STEP 1 trial, adults with obesity or overweight lost significantly more body weight on semaglutide 2.4 mg than on placebo over 68 weeks, and the SELECT cardiovascular-outcomes trial reported fewer major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity, without diabetes.[6]
SUSTAIN-6 similarly reported reduced cardiovascular events in people with type 2 diabetes at high cardiovascular risk. These are large, randomized, FDA-reviewed trials — a materially stronger evidence base than exists for most other peptides — though results are population- and dose-specific, and stopping treatment has been associated with weight regain in extension studies.[7]
Calculator
Plan your own dose
Reconstituting a different vial size or targeting a different dose? Run the numbers.
Reconstitution
Your dose
Other vial sizes